Aesica Pharmaceuticals Announces New Service Model

October 15, 2015
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 11, Issue 11

CDMO Aesica Pharmaceuticals introduced a new service approach in which the company will taks on the management of other CDMOs, while serving as the single, central point of customer contact, the company announced in an Oct. 14, 2015 press release.

CDMO Aesica Pharmaceuticals introduced a new service approach in which the company will taks on the management of other CDMOs, while serving as the single, central point of customer contact, the company announced in an Oct. 14, 2015 press release.

This model enables Aesica to identify which are the most strategically useful and effective CDMOs to engage in projects and to reduce the number of CDMOs that the customer must manage. This solution, which streamlines processes and creates a simplified supply-chain structure, achieves the goal of reducing the overall number of supplier relationships, while at the same time maintaining a consistent outsourcing approach across an entire portfolio. It also serves to guarantee “On Time In Full (OTIF)” product delivery, optimize efficiency, eliminate waste and supply shortages, and to achieve significant cost savings. Moreover, full visibility is achieved across the entire end-to-end manufacturing process.

The company already manages a portfolio of more than 10 different CDMOs and has assigned its own dedicated team responsible for ensuring total process management across an entire supply chain. This includes procurement to manage the relationship, risk assessment and price negotiations between customers, Aesica, and the other CDMOs. Moreover, the team is charged with responsibility for quality (to manage quality control and quality assurance activities) and the supply chain (to manage the delivery of components, including API for bulk production at the CDMO and then onward delivery to various sites for final processing).

The model is primarily geared to small and medium sized CDMOs, who face the same price pressures as big pharma, but lack all the skill sets and resources required for managing multiple CDMOs. It is also suited to companies that have diverse portfolios with affiliates or licensees based across multiple geographic regions.

Aesica also launched a new brand identity that reflects the new alignment and consolidation of the Consort Medical group, the company announced in an Oct. 12, 2015 press release. Aesica, which provides API and finished dose formulation development and manufacturing services, and Bespak, which develops and manufactures drug delivery devices, provide a single source for drug dosage forms and devices as companies in the Consort Medical group. The new logo has been inspired by the ‘joining together’ of the companies, with a three-cornered vertex designed to represent a dynamic company that is at the leading edge of innovation, the company announced at its launch at CPhI.

Source: Aesica